VivoSeq
Other

Intraarticular

1

Pipeline Programs

1

Active Trials

3

Companies Involved

Intraarticular is an early-stage landscape with 1 program across 3 companies. The most active players are Taiwan Bio Therapeutics Inc., Revance Therapeutics, Inc., 4Moving Biotech.

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

57/100

Attrition Rate

27/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Trial Status

11

clinical trials

Completed4 · 36%
Unknown status3 · 27%
Terminated2 · 18%
Withdrawn1 · 9%
Recruiting1 · 9%

Trial Activity

11 trials

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)